Scarica l'app Stockscreener
2.045
1.74%
0.035
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ATXI Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.01
Aprire:
$1.95
Volume 24 ore:
5,041
Relative Volume:
0.12
Capitalizzazione di mercato:
$2.79M
Reddito:
-
Utile/perdita netta:
$-10.38M
Rapporto P/E:
-0.4086
EPS:
-5.0046
Flusso di cassa netto:
$-12.45M
1 W Prestazione:
+8.78%
1M Prestazione:
+2.25%
6M Prestazione:
-46.18%
1 anno Prestazione:
-86.11%
Intervallo 1D:
$1.95
$2.06
Intervallo di 1 settimana:
$1.60
$2.06
Portata 52W:
$1.60
$26.47
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Nome
Avenue Therapeutics Inc
Settore
Industria
Telefono
781-652-4500
Indirizzo
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Confronta ATXI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ATXI | 2.06 | 2.79M | 0 | -10.38M | -12.45M | -5.0046 |
| VRTX | 449.83 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.11 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 594.70 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.75 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.87 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie
Avenue Therapeutics stock hits 52-week low at $1.68 - Investing.com
Avenue Therapeutics Inc (ATXI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires Additional Shares in Avenue Ther - GuruFocus.com
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Canadian North Resources Inc. Announces Appointment Of Henderson Tse To The Board Of Directors - The Manila Times
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Expedia faces threat from tepid growth in 2025, Deutsche Bank says after downgrade - Investing.com
Avenue Therapeutics director Jay Kranzler sells $136 in stock - Investing.com India
Avenue Therapeutics director Jay Kranzler sells $136 in stock By Investing.com - Investing.com UK
APLT (Applied Therapeutics) Cash From Other Investing Activities : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Drug Resistant Epilepsy Market Size, Industry Analysis, - openPR
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
NYC officials envision turning Fifth Avenue into a grand boulevard | Company Business News - Mint
Avenue Therapeutics stock hits 52-week low at $1.89 By Investing.com - Investing.com Australia
Avenue Therapeutics stock hits 52-week low at $1.89 - Investing.com
Park Avenue Securities LLC Reduces Position in Morningstar, Inc. (NASDAQ:MORN) - Defense World
DMart Q2 Results: Avenue Supermarts net profit rises 5.77% to ₹659.58 crore, revenue up 14.41% YoY | Company Business News - Mint
IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Park Avenue Securities LLC - Defense World
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - GlobeNewswire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - StockTitan
Avenue Therapeutics stock hits 52-week low at $2.17 By Investing.com - Investing.com South Africa
Avenue Therapeutics stock hits 52-week low at $2.17 - Investing.com
Avenue Therapeutics director buys shares worth $1,249 By Investing.com - Investing.com South Africa
Avenue Therapeutics director buys shares worth $1,249 - Investing.com India
Frazier Life Sciences Management L.P. Increases Stock Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Avenue Therapeutics grants stock units to top executives By Investing.com - Investing.com Canada
Avenue Therapeutics grants stock units to top executives - Investing.com India
Avenue Therapeutics Incentive Plan Awards Key Executives - TipRanks
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Avenue Therapeutics stock hits 52-week low at $2.23 By Investing.com - Investing.com Canada
Avenue Therapeutics stock hits 52-week low at $2.23 - Investing.com
Avenue Supermart shares rise 1.49% as Sensex climbs - The Economic Times
Avenue Supermart rises 1.49% as Sensex climbs - The Economic Times
Share price of Avenue Supermart falls as Sensex gains 251.05 points - The Economic Times
Victory Capital Management Inc. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Forest Avenue Capital Management LP Has $44.92 Million Position in Walmart Inc. (NYSE:WMT) - Defense World
Postoperative acute pain Market Size is Set for Rapid Growth as - openPR
Forest Avenue Capital Management LP Has $24.54 Million Holdings in GE Vernova Inc. (NYSE:GEV) - Defense World
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Amplia Therapeutics’ Drug Fast-Tracked by FDA - TipRanks
First Avenue IPO on Nomu 740% oversubscribed; offer price set at SAR 6 - بوابة أرقام المالية
Avenue Supermart shares down 0.27% as Nifty gains - The Economic Times
Avenue Supermart shares fall 0.27 per cent in Thursday's trading session - The Economic Times
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - AccessWire
Avenue Supermart shares up 0.35% as Nifty gains - The Economic Times
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
2 Dead In Series Of Police Shootouts That Shut Down Victory Boulevard - Patch
Meet Microsoft’s new COO—a former superstar CFO from GE - Fortune
Share price of Avenue Supermart rises as Nifty strengthens - The Economic Times
Allarity Therapeutics appoints new CFO - Investing.com India
Avenue Therapeutics Inc Azioni (ATXI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Avenue Therapeutics Inc Azioni (ATXI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KRANZLER JAY D | Director |
Sep 30 '24 |
Buy |
2.50 |
497 |
1,242 |
620 |
| KRANZLER JAY D | Director |
Sep 27 '24 |
Buy |
2.40 |
3 |
7 |
123 |
| Davidow Robert L | 10% Owner |
Dec 11 '23 |
Sale |
0.14 |
353,000 |
49,600 |
22,000 |
| Davidow Robert L | 10% Owner |
Dec 11 '23 |
Sale |
0.14 |
264,000 |
36,960 |
681,000 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):